Meeting of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, 5671-5672 [2020-01872]
Download as PDF
Federal Register / Vol. 85, No. 21 / Friday, January 31, 2020 / Notices
During the March 2–4, 2020, meeting,
NACRHHS will examine two topics:
Maternal and Obstetric Care Challenges
in Rural America and HIV Prevention
and Treatment Challenges in Rural
America. Refer to the NACRHHS
website for any updated information
concerning the meeting.
Members of the public will have the
opportunity to provide comments.
Public participants may submit written
statements in advance of the scheduled
meeting. Oral comments will be
honored in the order they are requested
and may be limited as time allows.
Requests to submit a written statement
or make oral comments to NACRHHS
should be sent to Steven Hirsch, using
the contact information above, at least 3
business days prior to the meeting.
Individuals who plan to attend and
need special assistance or another
reasonable accommodation should
notify Steven Hirsch at the address and
phone number listed above at least 10
business days prior to the meeting.
Since the meeting at the CDC occurs in
a federal government building,
attendees must go through a security
check to enter the building. Non-U.S.
Citizen attendees must notify Steven
Hirsch of their planned attendance at
least 20 business days prior to the
meeting in order to facilitate their entry
into the building. All attendees are
required to present government-issued
identification prior to entry.
Maria G. Button,
Director, Division of the Executive Secretariat.
[FR Doc. 2020–01810 Filed 1–30–20; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the National Clinical Care
Commission
Office of Disease Prevention
and Health Promotion, Office of the
Assistant Secretary for Health, Office of
the Secretary, Department of Health and
Human Services.
AGENCY:
ACTION:
Notice.
The National Clinical Care
Commission (the Commission) will
conduct a virtual meeting on February
19, 2020. The Commission is charged to
evaluate and make recommendations to
the U.S. Department of Health and
Human Services (HHS) Secretary and
Congress regarding improvements to the
coordination and leveraging of federal
programs related to diabetes and its
complications.
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:16 Jan 30, 2020
Jkt 250001
The meeting will take place on
February 19, 2020, from 1 p.m. to
approximately 5 p.m. Eastern Standard
Time (EST).
ADDRESSES: The meeting will be held
online via webinar. To register to attend
the meeting, please visit the registration
website at https://
kauffmaninc.adobeconnect.com/nccc_
feb2020/event/event_info.html.
FOR FURTHER INFORMATION CONTACT:
Linda Harris, Designated Federal
Officer, National Clinical Care
Commission, U.S. Department of Health
and Human Services, Office of the
Assistant Secretary for Health, Office of
Disease Prevention and Health
Promotion, 1101 Wootton Parkway,
Suite 420, Rockville, MD 20852. Email:
OHQ@hhs.gov. Telephone: 240–453–
8262.
SUPPLEMENTARY INFORMATION: The
National Clinical Care Commission Act
(Pub. L. 115–80) requires the HHS
Secretary to establish the National
Clinical Care Commission. The
Commission consists of representatives
of specific federal agencies and nonfederal individuals and entities who
represent diverse disciplines and views.
The Commission will evaluate and
make recommendations to the HHS
Secretary and Congress regarding
improvements to the coordination and
leveraging of federal programs related to
diabetes and its complications.
The sixth meeting will be held
virtually, and will consist of
presentations from the Centers for
Medicare and Medicaid Services (CMS).
The final meeting agenda will be
available prior to the meeting at https://
health.gov/hcq/national-clinical-carecommission.asp.
Public Participation at Meeting: The
Commission invites public comment on
issues related to the Commission’s
charge. There will be an opportunity for
oral comments at this virtual meeting.
Virtual attendees who plan to provide
oral comments at the Commission
meeting during a designated time must
register prior to the meeting. To
virtually attend the Commission
meeting, individuals must pre-register at
the registration website at https://
kauffmaninc.adobeconnect.com/nccc_
feb2020/event/event_info.html.
Written comments are welcome
throughout the entire development
process of the Commission’s work and
may be emailed to OHQ@hhs.gov, or by
mail to the following address: Public
Commentary, National Clinical Care
Commission, 1101 Wootton Parkway,
Suite 420, Rockville, MD 20852. Written
comments should not exceed three
pages in length.
DATES:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
5671
Individuals who need special
assistance with reasonable
accommodations, should indicate the
special accommodation when
registering online or by notifying
Jennifer Gillissen at jennifer.gillissen@
kauffmaninc.com by February 7, 2020.
Authority: The National Clinical Care
Commission is required under the
National Clinical Care Commission Act
(Pub. L. 115–80). The Commission is
governed by provisions of the Federal
Advisory Committee Act (FACA), Public
Law 92–463, as amended (5 U.S.C.,
App.) which sets forth standards for the
formation and use of federal advisory
committees.
Dated: January 23, 2020.
Donald Wright,
Deputy Assistant Secretary for Health.
[FR Doc. 2020–01871 Filed 1–30–20; 8:45 am]
BILLING CODE 4150–32–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on Combating AntibioticResistant Bacteria
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that a meeting is scheduled to be held
for the Presidential Advisory Council on
Combating Antibiotic-Resistant Bacteria
(PACCARB). The meeting will be open
to the public; a public comment session
will be held during the meeting. Preregistration is required for members of
the public who wish to attend the
meeting and who wish to participate in
the public comment session. Individuals
who wish to attend the meeting and/or
send in their public comment via email
should send an email to CARB@hhs.gov.
Registration information is available on
the website https://www.hhs.gov/paccarb
and must be completed by February 19,
2020; all in-person attendees must preregister by this date. Additional
information about registering for the
meeting and providing public comment
can be obtained at https://www.hhs.gov/
paccarb on the Meetings page.
DATES: The meeting is scheduled to be
held on February 26, 2020, from 9:00
a.m. to 4:30 p.m. and February 27, 2020,
from 9:00 a.m. to 4:00 p.m. ET (times are
tentative and subject to change). The
confirmed times and agenda items for
SUMMARY:
E:\FR\FM\31JAN1.SGM
31JAN1
jbell on DSKJLSW7X2PROD with NOTICES
5672
Federal Register / Vol. 85, No. 21 / Friday, January 31, 2020 / Notices
the meeting will be posted on the
website for the PACCARB at https://
www.hhs.gov/paccarb when this
information becomes available. Preregistration for attending the meeting in
person is required to be completed no
later than February 19, 2020; public
attendance at the meeting is limited to
the available space.
ADDRESSES: Hubert H. Humphrey
Building, The Great Hall, 200
Independence Ave. SW, Washington,
DC 20201. The meeting can also be
accessed through a live webcast and via
teleconference on the day of the
meeting. For more information, visit
https://www.hhs.gov/paccarb.
FOR FURTHER INFORMATION CONTACT:
Jomana Musmar, M.S., Ph.D.,
Designated Federal Officer, Presidential
Advisory Council on Combating
Antibiotic-Resistant Bacteria, Office of
the Assistant Secretary for Health, U.S.
Department of Health and Human
Services, Room L616, Switzer Building,
330 C St. SW, Washington, DC 20201.
Email: CARB@hhs.gov. Telephone: (202)
795–7678.
SUPPLEMENTARY INFORMATION: The
Presidential Advisory Council on
Combating Antibiotic-Resistant Bacteria
(PACCARB), established by Executive
Order 13676, is continued by Section
505 of Public Law 116–22, the
Pandemic and All-Hazards
Preparedness and Advancing Innovation
Act of 2019 (PAHPAIA). Activities and
duties of the Advisory Council are
governed by the provisions of the
Federal Advisory Committee Act
(FACA), Public Law 92–463, as
amended (5 U.S.C. App.), which sets
forth standards for the formation and
use of federal advisory committees.
The PACCARB shall advise and
provide information and
recommendations to the Secretary
regarding programs and policies
intended to reduce or combat antibioticresistant bacteria that may present a
public health threat and improve
capabilities to prevent, diagnose,
mitigate, or treat such resistance. The
PACCARB shall function solely for
advisory purposes.
Such advice, information, and
recommendations may be related to
improving: The effectiveness of
antibiotics; research and advanced
research on, and the development of,
improved and innovative methods for
combating or reducing antibiotic
resistance, including new treatments,
rapid point-of-care diagnostics,
alternatives to antibiotics, including
alternatives to animal antibiotics, and
antimicrobial stewardship activities;
surveillance of antibiotic-resistant
VerDate Sep<11>2014
17:16 Jan 30, 2020
Jkt 250001
bacterial infections, including publicly
available and up-to-date information on
resistance to antibiotics; education for
health care providers and the public
with respect to up-to-date information
on antibiotic resistance and ways to
reduce or combat such resistance to
antibiotics related to humans and
animals; methods to prevent or reduce
the transmission of antibiotic-resistant
bacterial infections; including
stewardship programs; and coordination
with respect to international efforts in
order to inform and advance the United
States capabilities to combat antibiotic
resistance.
The February 26–27 public meeting
will be dedicated to the swearing-in of
four new voting members, and
acknowledging the dedication of retiring
voting members. The remainder of the
two-day public meeting will include
antimicrobial (AMR)-focused panel
presentations and council discussions
on topics ranging from: Innovations to
disease prevention and management for
both human and animal health, the
changing AMR landscape, the gut
microbiome, and the future demand for
food production, with an in depth look
at aquaculture production and
management practices. The meeting
agenda will be posted on the PACCARB
website at https://www.hhs.gov/paccarb
when it has been finalized. All agenda
items are tentative and subject to
change.
Public attendance at the meeting is
limited to the available space.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the PACCARB at the address/
telephone number listed above at least
one week prior to the meeting. For those
unable to attend in person, a live
webcast will be available. More
information on registration and
accessing the webcast can be found at
https://www.hhs.gov/paccarb.
Members of the public will have the
opportunity to provide comments prior
to the public meeting by emailing
CARB@hhs.gov. Public comments
should be sent in by midnight February
10, 2020, and should be limited to no
more than one page.
Dated: January 10, 2020.
Jomana F. Musmar,
Designated Federal Officer, Presidential
Advisory Council on Combating AntibioticResistant Bacteria, Committee Manager.
[FR Doc. 2020–01872 Filed 1–30–20; 8:45 am]
BILLING CODE 4150–44–P
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Virology—A Study Section.
Date: February 27–28, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn Bayside, 4875 North
Harbor Drive, San Diego, CA 92106.
Contact Person: Kenneth M. Izumi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3204,
MSC 7808, Bethesda, MD 20892, 301–496–
6980, izumikm@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group; Neurotoxicology
and Alcohol Study Section.
Date: February 27–28, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crown Plaza River Oaks, 2712
Southwest Fwy., Houston, TX 77098.
Contact Person: Sepandarmaz Aschrafi,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040D,
Bethesda, MD 20892, (301) 451–4251,
Armaz.aschrafi@nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Neurogenesis and Cell Fate
Study Section.
Date: February 27, 2020.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marines Memorial Club and Hotel,
609 Sutter St., San Francisco, CA 94102.
Contact Person: Joanne T. Fujii, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4184,
MSC 7850, Bethesda, MD 20892, (301) 435–
1178, fujiij@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
E:\FR\FM\31JAN1.SGM
31JAN1
Agencies
[Federal Register Volume 85, Number 21 (Friday, January 31, 2020)]
[Notices]
[Pages 5671-5672]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-01872]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Presidential Advisory Council on Combating
Antibiotic-Resistant Bacteria
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the
Department of Health and Human Services (HHS) is hereby giving notice
that a meeting is scheduled to be held for the Presidential Advisory
Council on Combating Antibiotic-Resistant Bacteria (PACCARB). The
meeting will be open to the public; a public comment session will be
held during the meeting. Pre-registration is required for members of
the public who wish to attend the meeting and who wish to participate
in the public comment session. Individuals who wish to attend the
meeting and/or send in their public comment via email should send an
email to [email protected]. Registration information is available on the
website https://www.hhs.gov/paccarb and must be completed by February
19, 2020; all in-person attendees must pre-register by this date.
Additional information about registering for the meeting and providing
public comment can be obtained at https://www.hhs.gov/paccarb on the
Meetings page.
DATES: The meeting is scheduled to be held on February 26, 2020, from
9:00 a.m. to 4:30 p.m. and February 27, 2020, from 9:00 a.m. to 4:00
p.m. ET (times are tentative and subject to change). The confirmed
times and agenda items for
[[Page 5672]]
the meeting will be posted on the website for the PACCARB at https://www.hhs.gov/paccarb when this information becomes available. Pre-
registration for attending the meeting in person is required to be
completed no later than February 19, 2020; public attendance at the
meeting is limited to the available space.
ADDRESSES: Hubert H. Humphrey Building, The Great Hall, 200
Independence Ave. SW, Washington, DC 20201. The meeting can also be
accessed through a live webcast and via teleconference on the day of
the meeting. For more information, visit https://www.hhs.gov/paccarb.
FOR FURTHER INFORMATION CONTACT: Jomana Musmar, M.S., Ph.D., Designated
Federal Officer, Presidential Advisory Council on Combating Antibiotic-
Resistant Bacteria, Office of the Assistant Secretary for Health, U.S.
Department of Health and Human Services, Room L616, Switzer Building,
330 C St. SW, Washington, DC 20201. Email: [email protected]. Telephone:
(202) 795-7678.
SUPPLEMENTARY INFORMATION: The Presidential Advisory Council on
Combating Antibiotic-Resistant Bacteria (PACCARB), established by
Executive Order 13676, is continued by Section 505 of Public Law 116-
22, the Pandemic and All-Hazards Preparedness and Advancing Innovation
Act of 2019 (PAHPAIA). Activities and duties of the Advisory Council
are governed by the provisions of the Federal Advisory Committee Act
(FACA), Public Law 92-463, as amended (5 U.S.C. App.), which sets forth
standards for the formation and use of federal advisory committees.
The PACCARB shall advise and provide information and
recommendations to the Secretary regarding programs and policies
intended to reduce or combat antibiotic-resistant bacteria that may
present a public health threat and improve capabilities to prevent,
diagnose, mitigate, or treat such resistance. The PACCARB shall
function solely for advisory purposes.
Such advice, information, and recommendations may be related to
improving: The effectiveness of antibiotics; research and advanced
research on, and the development of, improved and innovative methods
for combating or reducing antibiotic resistance, including new
treatments, rapid point-of-care diagnostics, alternatives to
antibiotics, including alternatives to animal antibiotics, and
antimicrobial stewardship activities; surveillance of antibiotic-
resistant bacterial infections, including publicly available and up-to-
date information on resistance to antibiotics; education for health
care providers and the public with respect to up-to-date information on
antibiotic resistance and ways to reduce or combat such resistance to
antibiotics related to humans and animals; methods to prevent or reduce
the transmission of antibiotic-resistant bacterial infections;
including stewardship programs; and coordination with respect to
international efforts in order to inform and advance the United States
capabilities to combat antibiotic resistance.
The February 26-27 public meeting will be dedicated to the
swearing-in of four new voting members, and acknowledging the
dedication of retiring voting members. The remainder of the two-day
public meeting will include antimicrobial (AMR)-focused panel
presentations and council discussions on topics ranging from:
Innovations to disease prevention and management for both human and
animal health, the changing AMR landscape, the gut microbiome, and the
future demand for food production, with an in depth look at aquaculture
production and management practices. The meeting agenda will be posted
on the PACCARB website at https://www.hhs.gov/paccarb when it has been
finalized. All agenda items are tentative and subject to change.
Public attendance at the meeting is limited to the available space.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify the PACCARB at the address/telephone number listed above at
least one week prior to the meeting. For those unable to attend in
person, a live webcast will be available. More information on
registration and accessing the webcast can be found at https://www.hhs.gov/paccarb.
Members of the public will have the opportunity to provide comments
prior to the public meeting by emailing [email protected]. Public comments
should be sent in by midnight February 10, 2020, and should be limited
to no more than one page.
Dated: January 10, 2020.
Jomana F. Musmar,
Designated Federal Officer, Presidential Advisory Council on Combating
Antibiotic-Resistant Bacteria, Committee Manager.
[FR Doc. 2020-01872 Filed 1-30-20; 8:45 am]
BILLING CODE 4150-44-P